Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H14ClN3O4S |
Molecular Weight | 367.807 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](C(=O)N[C@H]1[C@H]2SCC(Cl)=C(N2C1=O)C(O)=O)C3=CC=CC=C3
InChI
InChIKey=QYIYFLOTGYLRGG-GPCCPHFNSA-N
InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1
Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly.
CNS Activity
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Oral pharmacokinetics of cefaclor in Mexican subjects. | 2001 |
|
Encouraging good antimicrobial prescribing practice: a review of antibiotic prescribing policies used in the South East Region of England. | 2001 |
|
Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. | 2001 |
|
Immunopharmacology of antibiotics: direct and indirect immunomodulation of defence mechanisms. | 2001 Apr |
|
Recurrent temporal petrositis. | 2001 Apr |
|
Desirable and undesirable immunotropic effects of antibiotics: immunomodulating properties of cefaclor. | 2001 Dec |
|
Antibiotic susceptibilities among recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis from fifteen countries. | 2001 Jan |
|
Spectrophotometric determination of selected cephalosporins in drug formulations using flow injection analysis. | 2001 Jul |
|
Evaluation of oral antimicrobial agent levels in tooth extraction sites. | 2001 Jun |
|
What have we learned from pharmacokinetic and pharmacodynamic theories? | 2001 Mar 15 |
|
In vitro and in vivo antibacterial activity and pharmacokinetics of SC-002 and its derivative, SC-004: new oral cephalosporins. | 2001 May-Jun |
|
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
Tolerability of 3-day, once-daily azithromycin suspension versus standard treatments for community-acquired paediatric infectious diseases. | 2001 Nov |
|
Antimicrobial susceptibility of Haemophilus influenzae among children in Beijing, China, 1999-2000. | 2002 |
|
Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin. | 2002 Apr |
|
Immunoglobulin E binding determinants on beta-lactam drugs. | 2002 Aug |
|
An unusual abdominal mass in a renal transplant recipient. | 2002 Dec |
|
Determination of antimicrobial activity of Cefaclor on common respiratory tract pathogens in Pakistan. | 2002 Jan |
|
Comparative study of cefaclor AF vs. cefuroxime axetil in acute exacerbations of chronic bronchitis. | 2002 Jan |
|
Foreign drug firm pleads guilty to felony charges. | 2002 Jan-Feb |
|
Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries. | 2002 Jul |
|
Susceptibility change to antibiotics of Staphylococcus aureus strains isolated from skin infections between July 1994 and November 2000. | 2002 Jun |
|
Serum sickness-like reactions. | 2002 May |
|
beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin. | 2002 Nov |
|
A case of purpuric drug eruption due to cefaclor. | 2002 Nov |
|
An evaluation of cefaclor in Pakistani children with pharyngotonsillitis. | 2002 Oct |
|
[Antimicrobial susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolated in major hospitals in Nagano Prefecture]. | 2002 Oct |
|
Cefaclor induced serum sickness like reaction. | 2002 Oct |
|
Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China. | 2003 Aug |
|
Modelling and analysing exchangeable binary data with random cluster sizes. | 2003 Aug 15 |
|
[In vitro sensitivity to antimicrobial agents of Haemophilus influenzae strains isolated from clinical specimens]. | 2003 Jan |
|
[Antibiotic resistance and serotype distribution of Streptococcus pneumoniae strains isolated from patients at Hacettepe University Medical Faculty]. | 2003 Jan |
|
Etiology of acute otitis media in childhood and evaluation of two different protocols of antibiotic therapy: 10 days cefaclor vs. 3 days azitromycin. | 2003 Jan |
|
Effect of extended-spectrum beta-lactamases on the susceptibility of Haemophilus influenzae to cephalosporins. | 2003 Jan |
|
Sensitive determination of a beta-lactam antibiotic, cefaclor by liquid chromatography with chemiluminescence detection. | 2003 Jan 15 |
|
Determination of cefaclor in human plasma by a sensitive and specific liquid chromatographic-tandem mass spectrometric method. | 2003 Jan 25 |
|
Natural antibiotic susceptibility of strains of Serratia marcescens and the S. liquefaciens complex: S. liquefaciens sensu stricto, S. proteamaculans and S. grimesii. | 2003 Jul |
|
How can we predict bacterial eradication? | 2003 Mar |
|
Effect of computerised prescribing on use of antibiotics. | 2003 Mar 3 |
Sample Use Guides
The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled.
Route of Administration:
Oral
Cefaclor inhibits the gram-negative bacteria. At a level of 12.5 ug/ml, 73% of the E. coli, 90% of the Salmonella, 55% of the Shigella, 77% of the Citrobacter, 91% of the Klebsiella, and 75% of the P. mirabilis isolates were inhibited. However, only 18% of the Enterobacter, 3% of the Serratia, 9% of the Proteus morganii, and 16% of the Providencia strains, and less than 10% of the Proteus vulgaris, Proteus rettgeri, and Bacteroides fragilis isolates, were inhibited. All Pseudomonas strains were as resistant to cefaclor as they were to available cephalosporins.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175488
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
WHO-ATC |
J01DC04
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
||
|
NDF-RT |
N0000011161
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
53994-73-3
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
PRIMARY | |||
|
4086
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
PRIMARY | |||
|
C76033
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
PRIMARY | |||
|
SUB06163MIG
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
PRIMARY | |||
|
DB00833
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
PRIMARY | |||
|
1450910
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
PRIMARY | RxNorm | ||
|
53994-73-3
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
PRIMARY | |||
|
53994-73-3
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
PRIMARY | |||
|
M3184
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
PRIMARY | Merck Index | ||
|
258-909-5
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
PRIMARY | |||
|
51039
Created by
admin on Mon Oct 21 22:33:23 UTC 2019 , Edited by admin on Mon Oct 21 22:33:23 UTC 2019
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)